BioInformant

Your Global Leader in Stem Cell Market Research

Restoration of Whole-Person Health: Re-envisioning Global Access

By Leave a Comment

*Sponsored Content: The article is sponsored by HEALInc.

Scientists increasingly agree that the convergence of advanced longevity technologies and regenerative medicines offers great promise for chronic disease prevention and optimal health throughout the individual’s lifespan. Thought leaders in these fields lament that in the rapidly evolving medical landscape, the journey from groundbreaking research to practical application is often fraught with challenges. HEALinc, a future health research and development (R&D) organization founded by Dr. Desirée Cox, is dedicated to overcoming the “Valley of Death” hurdle and ensuring that life-changing, longevity-enhancing therapies reach those who need them most. [Read more…]

I Peace manufactures 100 lines of GMP iPS Cells cumulatively

By Leave a Comment

Proof of customer recognition of its quality and mass manufacturing capability

Palo Alto, CA, January 7, 2025 — Leading GMP cell CDMO I Peace, Inc., specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that the number of GMP-grade iPS cells manufactured has reached 100 lines. This achievement solidifies I Peace as a true leader in the realm of  iPS cell manufacturers, equipped with abundant experience in manufacturing GMP-grade iPS cells in compliance with global regulations. [Read more…]

Tolerance Bio Announces Scientific Advisory Board and $20.2M Seed Round to Advance Thymus-Based Therapies for Immune-Mediated Diseases

By Leave a Comment

World-class leaders in the thymus, immunology, oncology, cell therapy, and drug development will inform and support the Company’s efforts to preserve, restore, and manipulate the thymus to address immune diseases
Pacific 8 Ventures joined the seed round syndicate led by Columbus Venture Partners, with participation by Criteria Bio Ventures, Sessa Capital, BioAdvance, and Ben Franklin Technology Partners

PHILADELPHIA, December 19, 2024 –Tolerance Bio, Inc., a biopharma company pioneering innovative approaches to increasing healthspan by preserving, restoring, and manipulating the function of the thymus, the master regulator of immune tolerance, today announced the formation of its Scientific Advisory Board (SAB) and the completion of its oversubscribed $20.2M seed financing round. [Read more…]

Funding Flows Freely into Exosome Therapeutics in 2025

By 1 Comment

The therapeutic applications of exosomes, particularly those derived from stem cells and cancer cells, continue to expand in 2025, driving accelerated innovation in this dynamic market. Emerging trends highlight the potential of exosomes as both diagnostic tools and cell-free therapeutics, with increasing applications across diverse fields such as oncology, neurology, and regenerative medicine. In parallel, a growing number of life science companies are providing advanced tools and reagents to support exosome research, reflecting the sector’s rapid growth. [Read more…]

Shopping cart0
There are no products in the cart!
Continue shopping
0